News & Events

Phathom Pharmaceuticals Announces Leadership Succession Plan and Strengthens Board of Directors with New Appointments

September 27, 2019

Terrie Curran, President, Global Inflammation and Immunology Franchise at Celgene Corporation, to succeed David Socks as CEO Michael Cola, Terrie Curran, Heidi Kunz, and Chris Slavinsky appointed to Board of Directors   BUFFALO GROVE, ILLINOIS, September 27, 2019 – Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on the

Read More

Phathom Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

June 4, 2019

Menlo Park, Calif., June 4, 2019 – Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, today announced that David Socks, Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019

Read More

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

May 15, 2019

New Company and Collaboration To Develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe   Cambridge, Mass. and Menlo Park, Calif., May 15, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Frazier Healthcare Partners (“Frazier”) today announced a collaboration to

Read More

Media inquiries: If you are a reporter with questions about Phathom Pharmaceuticals, or if you would like to request an interview, please contact: